Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Organon & Co.

Orogen Royalties ( ($TSE:OGN) ) just unveiled an announcement. Orogen Royalties reported a record 2025 financial performance, with total revenue ri...

Orogen Royalties Posts Record 2025 Results and Eyes Strong 2026 on Ermitaño Upside

Kepler Capital analyst Torsten Sauter maintained a Buy rating on Logitech on March 19 and set a price target of CHF95.00. The company’s shares clos...

Kepler Capital  Sticks to Its Buy Rating for Logitech (LOGI)

The latest update is out from Orogen Royalties ( ($TSE:OGN) ). Orogen Royalties Inc. has decided not to proceed with its previously announced priva...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OGN	$6.36	0.00%	3.40M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OGN	$6.36	0%	3.40M
3
4
5
6

OGN

OGN

Get Organon & Co. Data in Excel

Get Organon & Co. Data in Excel